Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
Mã chứng khoánKARD
Tên công tyKardigan Inc
Ngày IPOJun 18, 2026
Giám đốc điều hànhGianakakos (Tassos Anastasios)
Số lượng nhân viên420
Loại chứng khoánOrdinary Share
Kết thúc năm tài chínhJun 18
Địa chỉ506 Carnegie Center Drive, Suite 201
Thành phốPRINCETON JUNCTION
Sàn giao dịch chứng khoánNASDAQ OMX - NASDAQ BASIC
Quốc giaUnited States of America
Mã bưu điện08540
Điện thoại14155733220
Trang webhttp://www.kardigan.bio
Mã chứng khoánKARD
Ngày IPOJun 18, 2026
Giám đốc điều hànhGianakakos (Tassos Anastasios)